美国食品和药物管理局批准Susvimo植入物用于治疗糖尿病斑点, FDA approves Susvimo implant for treating diabetic macular edema, offering six-month refills.

林业发展局已核准Susvimo(一个植入物,内含肉色素),用于治疗糖尿病血管水肿(DME),该病影响到2 900多万成年人,并可能造成视力丧失。 The FDA has approved Susvimo, an implant containing ranibizumab, for treating diabetic macular edema (DME), a condition that affects over 29 million adults and can cause vision loss. 这是DME的首次连续分娩治疗,减少了对频繁注射的需要。 This is the first continuous-delivery therapy for DME, reducing the need for frequent injections. 该植入器每六个月可重新填充一次,其效果与临床试验中的每月注射一样有效,80%的患者更喜欢。 The implant, which can be refilled every six months, was found to be as effective as monthly injections in clinical trials and was preferred by 80% of patients.